The Israel-based company has signed a non-binding term sheet to acquire a liquid biopsy diagnostics platform and secure a concurrent $15 million strategic equity investment.
The quality management system certification confirms commitment to delivering consistent products and services to the scientific community.
The joint consensus recommendation from AMP, ASCO, and CAP addresses variability in molecular profiling report formats across laboratories.
The CLIA-certified facility is now authorized to operate in all 50 states, expanding biomarker testing capabilities nationwide.
The action follows a federal court order that vacated the 2024 rule, reinstating FDA’s prior policy of enforcement discretion for laboratory-developed tests.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
The new interim CEO currently serves as senior vice president and chief operating officer at the organization.
Analysis of international surveillance data shows rising resistance to last-line antibiotics, with significant regional variations in treatment outcomes.